MRS shows abnormalities before symptoms in familial Alzheimer disease

Neurology
A K GodboltM N Rossor

Abstract

Pathologic change in Alzheimer disease (AD) begins some years before symptoms. MRS has the potential to detect metabolic abnormalities reflecting this early pathologic change. Presenilin 1 (PS1) and amyloid precursor protein (APP) mutation carriers have a nearly 100% risk of developing AD and may be studied prior to symptom onset. Short echo time proton MR spectra were acquired from a midline posterior cingulate voxel in presymptomatic carriers of PS1 or APP mutations ("presymptomatic mutation carriers" [PMCs]; n = 7) and age- and sex-matched control subjects (n = 6). Ratios of N-acetyl aspartate (NAA), myo-inositol (MI), and choline-containing compounds (Cho) to creatine (Cr) were measured and NAA/MI calculated. Regression analyses and t tests were performed after log transformation. PMC and control subjects were matched for age and sex. PMC subjects were 1.7 to 21.6 years (mean 9.8 years) before expected symptom onset, predicted from family-specific mean age at onset. Age did not significantly affect metabolite ratios. Geometric mean ratios in control subjects were as follows: NAA/Cr = 1.75, MI/Cr = 0.59, and NAA/MI = 2.95. NAA/Cr and NAA/MI were significantly reduced in PMC relative to controls (NAA/Cr mean decrease 10% [95%...Continue Reading

Citations

Apr 4, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Eva-Margarete SpurLeo L Cheng
Jun 17, 2011·International Psychogeriatrics·Tao WangYiru Fang
Apr 8, 2010·Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition·H Randall GriffithDaniel C Marson
May 6, 2008·Journal of Neurotrauma·Paula A CaseyCourtney L Robertson
Nov 8, 2006·Topics in Magnetic Resonance Imaging : TMRI·Valerie C AndersonJeffrey A Kaye
Sep 27, 2007·Journal of Computer Assisted Tomography·Malgorzata FranczakJohn L Ulmer
Jan 23, 2010·Dementia and Geriatric Cognitive Disorders·Shuang-Qing ChenFeng-Chao Zang
Sep 25, 2008·Neurosurgery·Paul E Kim, Chi Shing Zee
Sep 21, 2011·Neuropsychiatric Disease and Treatment·Napapon SailasutaBrian Ross
Feb 27, 2014·Radiology·Gülin OzUNKNOWN MRS Consensus Group
May 1, 2008·The British Journal of Radiology·K Kantarci
May 1, 2008·The British Journal of Radiology·R I Scahill, N C Fox
Jul 19, 2011·Expert Opinion on Drug Discovery·David BorsookLino Becerra
Aug 10, 2013·Neuroimaging Clinics of North America·Kejal Kantarci
Dec 17, 2008·Revue neurologique·L Guyant-MaréchalD Hannequin
Oct 28, 2008·Progress in Neurobiology·A Vania ApkarianPaul Y Geha
Dec 7, 2007·Morphologie : Bulletin De L'Association Des Anatomistes·Marie-Paule Boncoeur-MartelAntoine Maubon
Jun 17, 2008·Journal of Cellular and Molecular Medicine·Ignasi BarbaDavid Pozo
May 23, 2012·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Eric M McDadeKejal Kantarci
Mar 26, 2013·Journal of Magnetic Resonance Imaging : JMRI·Kejal Kantarci
Nov 19, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ana C LondonoFrancisco Lopera
Apr 17, 2007·Neurobiology of Aging·Johanna ObergMattias Lindberg
May 11, 2016·Neurology·Olga VoevodskayaUNKNOWN Swedish BioFINDER study group
Sep 13, 2011·Cephalalgia : an International Journal of Headache·Barbara PodestàStefano Calzolari
Feb 11, 2012·American Journal of Alzheimer's Disease and Other Dementias·Pedro J Modrego, Nicolás Fayed
Dec 14, 2009·The Neuroradiology Journal·H CuellarL De Alba
Dec 5, 2017·International Review of Psychiatry·Liana K MathiasBrent P Forester
Apr 20, 2014·AJNR. American Journal of Neuroradiology·F Gao, P B Barker
Jun 8, 2019·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Qin ChenKejal Kantarci
Jan 6, 2019·Neurology·Olga VoevodskayaUNKNOWN Swedish BioFINDER Study Group
May 8, 2018·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Daniela SmirniPatrizia Turriziani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.